Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • AUD/USD

    0.6521
    +0.0021 (+0.32%)
     
  • OIL

    82.95
    +0.14 (+0.17%)
     
  • GOLD

    2,333.80
    -4.60 (-0.20%)
     
  • Bitcoin AUD

    98,366.34
    -4,102.48 (-4.00%)
     
  • CMC Crypto 200

    1,390.10
    +7.53 (+0.54%)
     
  • AUD/EUR

    0.6082
    +0.0012 (+0.19%)
     
  • AUD/NZD

    1.0952
    +0.0010 (+0.09%)
     
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,078.93
    +38.55 (+0.48%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    17,986.24
    -102.46 (-0.57%)
     
  • Hang Seng

    17,279.23
    +77.96 (+0.45%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Micron (MU) Q4 Earnings Beat Estimates, Q1 EPS View Upsets

Micron Technology, Inc. MU reported fourth-quarter fiscal 2019 non-GAAP earnings per share of 56 cents, which surpassed the Zacks Consensus Estimate of 48 cents but were lower than the year-ago quarter’s figure of $3.53.

Meanwhile, Micron’s revenues of $4.87 billion in the quarter under review exceeded the Zacks Consensus Estimate of $4.52 billion but dropped around 42% on a year-over-year basis.

Although the company suffered a drastic year-over-year fall in revenues and earnings, its better-than-expected fourth-quarter fiscal 2019 results coupled with an improved 2020 outlook for DRAM are making investors hopeful.

Recovery in demand for DRAM and NAND owing to increased inventory levels at most customers is a positive.

However, the uncertainty hovering over trade and the economy is a major overhang on the company. Restriction on sales to Huawei negatively impacted the company’s revenues. Further, the company fears a worsening decline in sales to Huawei over the coming quarters in case it fails to secure the license to ship additional products to Huawei or if the trade ban is not removed.

Notably, the company’s weak earnings and gross margin guidance for fiscal 2020 is a point of concern. The company projects earnings in the range of 39-53 cents per share for the fiscal first quarter. The mid-point of 46 cents is significantly below the current Zacks Consensus Estimate of 52 cents.

Revenue Details

DRAM revenues of $3.1 billion, accounting for 63% of total revenues in the quarter under discussion, plunged 48% year over year. However, it inched up 1% sequentially. With improvement in customer inventories, bit shipments surged nearly 30% sequentially and in the mid-teens percent range year over year. On a sequential basis, ASP declined 20%.

Management mentioned that a significant depletion in customer inventories for DRAM led to strong sequential growth in demand for server solutions in both cloud and enterprise markets. Moreover, new processor platforms are boosting demand for higher-density and higher-performance DRAM modules.

In graphics market, increasing demand for graphics cards and gaming consoles aided solid sequential DRAM bit growth. Further, with CPU shortages subsiding, growth in DRAM module and SSD shipments was a positive in the PC market. Additionally, in automotive sector, the company continued to boost revenues on a year-over-year basis, despite waning auto industry unit sales and a tough DRAM industry environment.

NAND revenues of $1.5 billion, representing 31% of the total top line, were down 32% on a year-over-year basis but up 5% quarter over quarter. While NAND ASP decreased in the upper single-digit’s percentage band, shipment quantities improved in the low-to-mid teens percent range sequentially.

However, management mentioned that NAND prices are starting to surge. Moreover, the company is also seeing restrained supply in specific portions of the market.

Business unit wise, revenues of the computing and networking business (CNBU) unit deteriorated 56% from the year-ago quarter and 8% sequentially to $1.9 billion. Weak pricing across most market segments remained a dampener.

Revenues from the Mobile Business Unit (MBU) of $1.4 billion softened 26% on a year-over-year basis. The metric improved 20% sequentially though. A firm uptick in both DRAM and NAND bits owing to seasonality and persistent content growth in smartphones is a positive. The company’s reinforced product portfolio helped its mobile business gain shares.

The Embedded Business Unit revenues logged $705 million, down 24% from the year-ago quarter but up 1% from the previous quarter.

Revenues from the Storage Business Unit (SBU) comprising SSD NAND components and 3D XPoint totaled $848 million, down 32% on a year-over-year basis but up 4% sequentially.

Margins

Micron’s non-GAAP gross profit of $1.45 billion slumped 71% from the prior-year period. Non-GAAP gross margin fell from 61.3% in the year-ago quarter to 30.6%, attributable to lower pricing of both DRAM and NAND. Moreover, IMFT related underutilization charges had a negative impact of nearly 200 basis points.

Micron’s non-GAAP operating income of $694 million declined from $4.4 billion in the year-ago quarter. Non-GAAP operating margin contracted 38 bps to 14%.

Balance Sheet and Cash Flow

The company exited the quarter with cash and short-term investments of $7.955 billion compared with $6.689 billion at the end of the preceding quarter.

Micron’s long-term debt increased to $4.541 billion from $3.563 billion in the prior quarter.

The company generated operating cash flow of $2.2 billion compared with $2.7 billion in the previous quarter. Adjusted free cash flow during the reported quarter was $260 million, down from $500 million in the sequential quarter.

Guidance for Q1

For the first quarter of fiscal 2020, the company guided revenues of $4.8-$5.2 billion. The mid-point of $5 billion is above the current Zacks Consensus Estimate of $4.7 billion.

For the fiscal first quarter, Micron expects non-GAAP gross margin of 26.5% (+/- 150 bps). Higher mix of NAND, which has lower gross margin, coupled with falling memory prices and minimal decline in manufacturing cost is likely to keep margins under pressure.

Operating expenses on a non-GAAP basis are likely to be $780 million (+/- $25 million).

DRAM and NAND Outlook

For calendar 2019, DRAM bit demand is still envisioned to climb in mid-teens percentage with bit supply exceeding demand. While for calendar 2020, Micron expects the industry to see bit demand growth from high-teens to 20% range, higher than supply growth of only mid-teens.

Coming to NAND, demand elasticity and lower industry supply are leading to an improvement in market conditions and reducing industry inventory.

For 2019, NAND bit demand is assumed to grow by a low-to-mid 40s percentage range, up from mid-30s percentage increase assumed earlier.

On the supply side, cutting down on CapEx and wafer start across the industry is leading to supply reductions. Given this, Micron now expects industry bit supply growth of approximately 30% comparing with high-30s percentage rise expected earlier.

For 2020, the company expects industry’s NAND bit demand to grow in the high 20s to low 30 percentages with supply growth “somewhat below demand”.

Further, in order to draw a demand-supply balance, the company is trimming its fiscal 2020 front-end equipment CapEx by more than 30% year over year. Moreover, to tackle the market clog, the company announced that it will continue to idle 5% of its DRAM wafer starts and 10% of its NAND chip wafer starts.

Zacks Rank and Other Stocks to Consider

Currently, Micron has a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader technology sector are Rosetta Stone RST, Chegg CHGG and Perficient PRFT, each flaunting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Long-term earnings growth rate for Rosetta, Chegg and Perficient is currently projected to be 12.5%, 30% and 10.8%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Click to get this free report Chegg, Inc. (CHGG) : Free Stock Analysis Report Perficient, Inc. (PRFT) : Free Stock Analysis Report Rosetta Stone (RST) : Free Stock Analysis Report Micron Technology, Inc. (MU) : Free Stock Analysis Report To read this article on Zacks.com click here.